Show simple item record

dc.contributor.authorGuha, Sujoy K
dc.contributor.authorSingh, Gulshanjit
dc.contributor.authorSrivastava, Anil
dc.contributor.authorDas, H C
dc.contributor.authorBhardwaj, J C
dc.contributor.authorMathur, Vineet
dc.contributor.authorKoul, Veena
dc.contributor.authorMalhotra, R L
dc.contributor.authorDas, S K
dc.date.accessioned2005-07-28T08:53:45Z
dc.date.accessioned2019-02-09T07:13:03Z
dc.date.available2005-07-28T08:53:45Z
dc.date.available2019-02-09T07:13:03Z
dc.date.issued1998
dc.identifier.citationContraception, 58(3), 165–174en
dc.identifier.urihttp://localhost:8080/xmlui/handle/12345678/593
dc.description.abstractContraceptive action of a single intra–vas deferens injection of a specific preparation of styrene maleic anhydride (SMA) dissolved in dimethyl sulphoxide, forming a drug given the name Risugt, has been demonstrated earlier.Now fertility control over a 2-year period with doses having the SMA component ranging from 40 to 70 mg is reported here. The results suggest that pregnancy protection is obtained both in the azoospermic and non-azoospermic states. Side effects are minimal and transient in nature. Libido remains unaltered.en
dc.format.extent2010152 bytes
dc.format.mimetypeapplication/pdf
dc.language.isoenen
dc.subjectsingle injectionen
dc.subjectvas deferensen
dc.subjectmaleen
dc.subjectpregnancy protectionen
dc.subjectlibido maintenanceen
dc.titleTwo-year clinical efficacy trial with dose variations of a vas deferens injectable contraceptive for the maleen
dc.typeArticleen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record